Ollin Biosciences, Inc.

Ollin Biosciences, Inc. is an Austin, Texas-based clinical-stage biopharmaceutical company established in 2023 and publicly launched in September 2025. It describes itself as an asset-centric company that acquires and develops therapies for vision-threatening diseases, combining ophthalmology drug development expertise with data science and ophthalmic image analysis tools.

Its lead program, OLN324, is a VEGF/Ang2 bispecific antibody engineered for substantially higher Ang2 potency than faricimab, a smaller protein format, and higher molar dosing than both faricimab and aflibercept (including Eylea HD). It targets wet (neovascular) age-related macular degeneration and diabetic macular edema. OLN324 was discovered by Innovent Biologics (HKEX: 01801, R&D code IBI324) and is being developed in collaboration with Innovent. A prior Phase 1 single- and multiple-ascending-dose study in DME patients was conducted in China. The randomized, U.S.-based Phase 1b JADE proof-of-concept study (NCT07484074, started February 2025) enrolled 164 patients and compared OLN324 head-to-head with faricimab; the company reported faster and greater improvements in retinal anatomy in both DME and wAMD and numerically greater vision gains, with final data announced in March 2026 and presentations at the ASRS annual meeting in July 2026.

A second program, OLN102 (also referenced as VBS-102), is a TSHR/IGF-1R bispecific antibody for thyroid eye disease and the underlying autoimmune condition of Graves' disease, discovered by and developed in collaboration with VelaVigo. As of the Series B announcement it was expected to enter clinical development in 2026.

Founding story

The company was established in 2023 and emerged publicly in September 2025 with an initial $100 million financing. It was co-founded by Jason Ehrlich, M.D., Ph.D., who serves as chief executive officer and previously was chief medical officer and chief development officer at Kodiak Sciences; Travis Murdoch, M.D., is also identified in later coverage as a co-founder of Ollin. ARCH Venture Partners managing director Paul Berns serves as board chair, and ARCH is described as a founding investor alongside co-founding investors Mubadala Capital and Monograph Capital. Management has characterized the company as "purpose-built" to acquire and advance next-generation ophthalmology product candidates rather than to originate discovery-stage assets internally.

Business model

Ollin operates as an asset-centric biopharmaceutical developer that in-licenses or acquires clinical- and late-preclinical-stage ophthalmology candidates originated by other organizations (Innovent Biologics for OLN324, VelaVigo for OLN102) and advances them through clinical development and regulatory approval. Operations are funded by venture and institutional equity financing rather than product revenue.

Traction

Completed the 164-patient randomized Phase 1b JADE head-to-head study versus faricimab with reported anatomic and numerical vision advantages; completed an FDA End-of-Phase 2 meeting and received EMA scientific advice; raised approximately $430 million across a $100 million launch financing and a $330 million Series B; data selected for oral presentation at the ASRS 44th Annual Scientific Meeting in July 2026. Third-party data indicates a headcount range of 10-50.

Latest developments

On June 24, 2026 Ollin announced an oversubscribed $330 million Series B co-led by TCGX and ARCH Venture Partners, with TCGX Managing Partner Cariad Chester joining the board. Proceeds are earmarked for global Phase 3 trials of OLN324 in DME and wAMD starting in the second half of 2026 and for moving OLN102 into clinical development. In July 2026 the company announced oral presentations of JADE Phase 1b results at the ASRS annual meeting.